INTRODUCTION
============

Acute heart failure (AHF), either with reduced ejection fraction (HFrEF) or with preserved ejection fraction (HFpEF), remains an important cause of morbidity and mortality globally, especially for older adults, despite recent advances in treatment.[@B1][@B2][@B3] Moreover, there is increasing evidence that the prevalence of AHF is substantial in older adult patients complicated with hypertension, although evidence-based treatment strategies are generally lacking.[@B4] The development of novel pharmacologic agents for patients with both hypertension and AHF is urgently needed.

Long-term overload of the heart caused by elevated after-loading is a major clinical characteristic of hypertensive patients, particularly older adults. These patients typically exhibit reduced cardiac reserve and are therefore vulnerable to decompensated AHF after acute stimulus.[@B5] There is clinical evidence that the hemodynamic characteristics of AHF patients may be somewhat different from those with chronic heart failure.[@B6] Although all patients with either acute or chronic heart failure have impaired cardiac function, those with AHF are characterized by elevated filling pressures, high systemic vascular resistance, and hypertension. These features not only lead to "pump failure", but also further reduce perfusion to vital organs to cause vascular failure.[@B7][@B8]

Vasodilators have been accepted as the first-line treatment for patients with hypertension and AHF,[@B9][@B10][@B11] and nitroglycerin is the vasodilator most often administered. However, adverse effects associated with nitroglycerin, such as headache, flushing, and reflective tachycardia, can limit its use,[@B12][@B13] and no obvious benefits to cardiac systolic and diastolic function have been confirmed.[@B12]

Urapidil, a sympatholytic antihypertensive drug with cardioprotective effects exerted through the peripheral alpha-adrenergic receptor and via central 5-hydroxytryptamine (serotonin) receptor 1A (HTR1A) agonistic action may have great therapeutic potential for older patients with hypertension and AHF.[@B14][@B15] However, evidence from randomized controlled trials concerning this medication is limited.

In the present study, we evaluated the efficacy and safety of intravenous urapidil for older hypertensive patients with AHF (both HFrEF and HFpEF) relative to that of conventional vasodilator nitroglycerin. In particular, we performed a post-hoc subgroup analysis of the role of intravenous urapidil on left ventricular function in patients with HFpEF.

MATERIALS AND METHODS
=====================

This study is part of a multicenter clinical trial that was performed in 11 research centers in mainland China. The Ethics Committees of the included research centers approved the protocols of the study before its performance, and all the included patients and their relatives signed informed consent forms. The protocol of the clinical trial was registered in the Chinese Clinical Trial Registry (ChiCTR-TRC-11001781) before enrollment of the first patients. A subgroup portion of the current study, which included only AHF patients with diabetes, has been published previously.[@B16]

Patients and study protocol
---------------------------

This study was designed as an open-label randomized controlled trial to evaluate the efficacy and safety of intravenous urapidil relative to conventional vasodilator nitroglycerin for older hypertensive patients. These patients had also received diagnoses of AHF, and included patients with HFrEF and those with HFpEF. Enrollment occurred from August 1, 2011 to November 30, 2013. The included patients were randomly assigned via random number generation from a computer to either an urapidil-based treatment group (n=89) or a nitroglycerin-based control group (n=91). The group assignment of the patients was known to both the investigators and the participants.

Inclusion and exclusion criteria of the patients
------------------------------------------------

Patients were included in the current study if they fulfilled all of the following criteria: aged \>60 years; previous diagnosis of hypertension, defined as systolic blood pressure (SBP) \>140 mm Hg or diastolic blood pressure (DBP) of \>90 mm Hg, or regularly taking antihypertensives in accordance with the 2010 Chinese guidelines for the management of hypertension;[@B17] received a diagnosis of AHF, including either HFrEF or HFpEF, according to the 2014 Chinese guidelines for the diagnosis and treatment of heart failure;[@B18] and scheduled for inpatient treatment in the included medical centers. A diagnosis of AHF was mainly based on clinical manifestations (staged above Class II of the New York Heart Association Classification), observations on physical examination, and echocardiographic results.

Patients were excluded from the current study if they had any of the following: contraindications for intravenous administration of vasodilators, such as cardiogenic shock, SBP ≤100 mm Hg, cerebral ischemia, or severe stenosis of the carotid arteries; confirmed acute coronary syndrome; severe structural heart disease comorbidities, including severe valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or pericarditis; any severe condition involving other systems or organs, such as severe chronic asthmatic bronchial and pulmonary disease, severe liver dysfunction \[\>3-fold maximum normal values of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\], or kidney insufficiency (\>2-fold maximum normal value of creatinine); known or suspected allergy to any of the tested medications and their ingredients; end-stage disease as determined by researchers (e.g., cancer cachexia or severe mental illness); received the tested medications within 60 days before enrollment; or past or present involvement in other clinical research programs.

Medications and dosage titration methods
----------------------------------------

All the included patients were allowed to continue use of regular antihypertensives (including calcium-channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and diuretics) and intake of other cardiovascular medications (digoxin, amiodarone, and statins) during the study. Beta-blockers, which may confer an increased risk of deterioration of AHF, were not prescribed during the study period.

For patients assigned to the urapidil group, intravenous urapidil hydrochloride (Ebrantil, Byk Gulden, Konstanz, Germany; every 100 mg of urapidil diluted in 50 mL of normal saline) was continuously administered, and the dosages of the urapidil were adjusted according to the blood pressure of the patients. Generally, the administration of urapidil began at a small dose, depending on the clinical situation, and then gradually increased to the target dose (50 to 100 µg/min) within 6 h, with a maximum dose of 400 µg/min. Intravenous urapidil was discontinued if the SBP was \<90 mm Hg. However, if the symptoms of AHF were not relieved during the first 48 hours after the start of urapidil administration, it was discontinued and subsequent treatment was based on the judgment of the investigators.

For patients assigned to the nitroglycerin group, intravenous nitroglycerin (Beijing Yimin Pharmaceutical, Beijing, China; every 10 mg of nitroglycerin diluted in 50 mL of 5% glucose solution) was continuously administered. The starting dose of nitroglycerin began at a small dose, depending on the clinical situation, and then increased to the target dose (5 to 10 µg/min) within 6 h, with a maximum dose of 40 µg/min. The protocol for dosage adjustment and the criteria for the discontinuation of nitroglycerin were the same as for intravenous urapidil. Only patients who received the tested medications for more than 24 hours were included for subsequent analyses.

Outcomes of interest
--------------------

Each patient in the study underwent repeated assessment of hemodynamic parameters (i.e., heart rate, SBP, and DBP) at hospital admission (baseline) and after 1, 2, 3, and 7 days of intravenous vasodilator administration. Serum levels of N-terminal B type natriuretic peptide (NT-proBNP) were also evaluated at the same time points. Transthoracic echocardiography was performed to evaluate the systolic function of the left ventricles of the included patients, and the left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume (LVEDV) were also measured at hospital admission and 2 and 7 days after intravenous vasodilator administration. Serum parameters reflective of lipid levels and glucose metabolism and hepatic and renal functions were also evaluated at hospital admission and 2 and 7 days after intravenous vasodilator administration. No other intravenous vasodilators were used during this period.

The patients were followed for 1 month after discharge from the hospital. Clinical outcomes were evaluated for patients from each group, including heart failure-related rehospitalization, as well as all-cause mortality. We also investigated the rates of medication-related adverse events during the treatment periods, specifically headache, flushing, tachycardia, and hypotension.

Echocardiographic evaluation of left ventricular function
---------------------------------------------------------

Global left ventricle function was assessed by transthoracic echocardiography (Philips IE-33 Ultrasonic System, Philips, Amsterdam, the Netherlands). The apical 2- and 4-chamber views were chosen for the measurement of LVEF, used as an index of global left ventricular systolic function. To calculate LVEF, end-diastolic and end-systolic frames were selected, end-diastolic and end-systolic endocardial borders were manually traced, and biplane LVEF was calculated. LVEDV was also measured for each patient.

Statistical analyses
--------------------

The calculation of sample size was based on the previous findings of a pilot study, in which the difference in LVEF after urapidil therapy, as compared with those who received nitroglycerin, was 8% with a combined standard error (SE) of 16%. Assuming that the efficacy for the testing of type 1 error α=0.05 and the efficacy for the testing of type 2 error β=0.10, then the calculated sample size n in each group was:

Considering the potential loss of patients during the follow-up, the study was designed so that each group comprised 90 patients. Continuous data are presented as mean±standard deviation, and the categorical data are presented as numbers and frequencies. Each set of data was tested for normal distribution. Differences in the continuous and categorical data between the two groups were analyzed using Student's t-test or chi-squared analysis. Differences in the data at multiple time points between the two groups were analyzed using repeated-measures analysis of variance (ANOVA) and an independent-samples t-test. Statistical analyses were conducted with SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). A *p* value\<0.05 was considered statistically significant.

RESULTS
=======

Baseline characteristics of the included patients
-------------------------------------------------

In this study, 180 patients with both hypertension and AHF were enrolled from 11 medical centers in mainland China. Each center contributed 15--20 patients ([Table 1](#T1){ref-type="table"}). The ages of the patients varied from 60 to 88 years. In the urapidil group, the mean age was 77.5 years, with 51 men and 38 women. In the nitroglycerin group, the mean age was 76.9 years, with 54 men and 37 women.

The patients of the two groups were similar for demographic and clinical factors, such as age and gender, the duration of hypertension, manifestations of AHF (as evaluated by LVEF and distribution of New York Heart Association classifications), baseline renal function \[as evaluated by the estimated glomerular filtration rate (eGFR)\], comorbidities of coronary heart disease, diabetes mellitus, and atrial fibrillation, and cardiovascular medications, such as antihypertensives and digoxin (all *p*\>0.05). All of the included patients received the predetermined dosages of intravenous vasodilators in accordance with the assigned protocols. The mean treatment duration for nitroglycerin was 89 h, and the mean dosage was 86.4 mg per patient. The mean treatment duration for urapidil was 88 h, and mean dosage was 412.9 mg per patient.

Overall, 70 patients with HFpEF were included in the current analysis, of which 34 were randomized to the nitroglycerin group, while 36 were assigned to the urapidil group ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online). The patients with HFpEF assigned to the two groups were balanced for baseline characteristics, including gender, age, duration of hypertension, baseline LVEF and NT-proBNP, New York Heart Association classifications, and the antihypertensives used (*p*\>0.05).

SBP, DBP, and heart rate
------------------------

Repeated-measures ANOVA and results of multivariate analysis of the intra-group elements showed that in both the urapidil and nitroglycerin groups, 7 days of treatment were associated with significantly lower SBP (F=91.6), DBP (F=32.5), and heart rate (F=26.6) across the different time points ([Fig. 1](#F1){ref-type="fig"}).

Regarding SBP ([Fig. 1A](#F1){ref-type="fig"}), in patients of the urapidil group, reductions in SBP were observed after 1, 2, 3, and 7 days of treatment, and for those in the nitroglycerin group, reduced SBP also occurred within 7 days. However, at days 3 and 7, the mean SBPs of the urapidil group (126.3±5.2 and 110.1±6.5 mm Hg, respectively) were significantly lower than those of the nitroglycerin group (138.3±4.1 and 126.4±8.1 mm Hg; *p*=0.045, 0.022).

Regarding DBP and heart rate, the reductions in both groups within the 7 days were statistically similar ([Fig. 1B and C](#F1){ref-type="fig"}). These results indicated that, relative to nitroglycerin, urapidil was associated with better-controlled blood pressure, as reflected by the significantly decreased SBP after 3 and 7 days of treatment. However, this effect was not accompanied by a significant difference in heart rates between the two treatments.

Cardiac systolic function
-------------------------

Repeated-measures ANOVA and results of multivariate analysis of the intra-group elements showed that, in both the urapidil and nitroglycerin groups, serum NT-proBNP levels (F=21.7) were significantly lower at the end of 7 days of treatment ([Fig. 2A](#F2){ref-type="fig"}). The trends in reductions of serum NT-proBNP were similar at each time point, reaching a significant difference at day 7. That is, on day 7, serum levels of NT-proBNP of the urapidil group (3311.4±546.1 ng/mL; F=13.1) were significantly lower than that of the nitroglycerin group (4879.1±325.7 ng/mL; *p*=0.027). These results indicate that urapidil may be more effective in improving cardiac function than nitroglycerin for older patients with hypertension and AHF.

Patients in both groups had similar LVEFs and LVEDVs at admission and 2 days after the start of the respective vasodilator treatments ([Fig. 2B and C](#F2){ref-type="fig"}). After 7 days, the LVEF of patients in the urapidil group (62.2±3.4%) was significantly higher than that of patients given nitroglycerin (51.0±2.4%, *p*=0.032) ([Fig. 2B](#F2){ref-type="fig"}). This suggests that the effects of urapidil were more favorable than those of nitroglycerin on left ventricular function. Seven days after the start of treatment, the mean LVEDV of the urapidil group (145.2±13.4 mL) was significantly lower than that of the nitroglycerin group (167.6±11.2 mL, *p*=0.024) ([Fig. 2C](#F2){ref-type="fig"}). These data also support that the effect of intravenous urapidil on cardiac systolic function is more favorable for older patients with hypertension and AHF, compared with the conventional vasodilator nitroglycerin.

As for patients with HFpEF, although no significant differences in NT-proBNP were detected between patients from the two groups at 1 or 2 days after treatment, patients assigned to the urapidil group had significantly lower serum NT-proBNP at 3 days (4127.3±256.5 ng/mL vs. 5136.6±251.5 ng/mL, *p*=0.04) ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online) and 7 days after treatment (3256.4±237.4 ng/mL vs. 4534.2±35.4 ng/mL, *p*=0.02) ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online), compared to those treated with nitroglycerin. However, no significant differences in LVEF were detected between patients from the two groups within 7 days after treatment (*p*\>0.05, all; [Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online).

Biochemical indices of renal and liver function, blood lipids, and glucose metabolism
-------------------------------------------------------------------------------------

No significant changes, in either the urapidil or nitroglycerin group, were observed in serum indicators of renal function (eGFR), hepatic function (AST and ALT), blood lipids (triglycerides), or fasting plasma glucose during the 7 days after treatment ([Table 2](#T2){ref-type="table"}). This indicates that intravenous administration of urapidil, similar to the administration of nitroglycerin, is safe for older patients with hypertension and AHF.

Adverse events and clinical outcomes during follow-up
-----------------------------------------------------

The vasodilator nitroglycerin is known for its adverse effects of headache and reflective tachycardia. In this study, urapidil was associated with fewer incidences of headache (*p*=0.025) and tachycardia (*p*=0.004), compared with nitroglycerin, although flushing and hypotension were similar ([Table 3](#T3){ref-type="table"}). These results suggest that urapidil may be better tolerated by these patients.

At 1-month follow-up, the clinical outcomes of the two groups were not significantly different, specifically rates of hospitalization due to heart failure and all-cause mortality.

DISCUSSION
==========

In this multi-center randomized controlled trial, we evaluated the efficacy and safety of intravenous urapidil relative to that of conventional vasodilator nitroglycerin in patients older than 60 years with hypertension and AHF. The results showed that urapidil was associated with better-controlled blood pressure within 7 days of the treatment period, and its benefits on SBP were not accompanied by a change in heart rate. The significantly lower serum NT-proBNP, increased LVEF, and reduced LVEDV of patients given intravenous urapidil, relative to the nitroglycerin group, indicated better cardiac systolic function. Furthermore, results of the post-hoc analyses in patients with HFpEF indicated that urapidil treatment was associated with significantly lower NT-proBNP levels after 3 and 7 days of treatment, although LVEF was not significantly affected.

Intravenous urapidil showed no association with any impairment in renal or hepatic function, or disorders of blood glucose or lipid metabolism, and patients experienced fewer of the adverse events that are associated with other vasodilators, such as headache and tachycardia. Rehospitalization rates for AHF and all-cause mortality were not significantly different between the urapidil and nitroglycerin groups. Therefore, older hypertensive patients who suffer from AHF may receive more benefit from intravenous urapidil than nitroglycerin, indicated by the significantly more remarkable improvements in blood pressure and cardiac protective functions observed in this study. In addition, urapidil was safer and better tolerated in these patients.

Early clinical evidence confirmed the potential role of vasodilators in patients with AHF.[@B7][@B19] Pathophysiologically, AHF was defined as an acutely insufficient status of the heart after significant increases in pressure or fluid overloads or a severe dysfunction of the cardiovascular system. Dramatic increases in blood pressure, particularly SBP, have been recognized as an important component of the pathophysiologic process. Either as an initial cause or as an intermediate feature, hypertension can lead to pressure overload, which further impairs cardiac function. More importantly, constriction of the peripheral arteries seen in hypertension can cause poor perfusion in important organs, thereby inducing systematic manifestations in patients with AHF. Therefore, the benefits of vasodilators in these circumstances are obvious, since they could lead to a significant reduction of the afterload of the heart and improve the perfusion of the vital organs. Indeed, clinical evidence has also revealed the therapeutic role of vasodilators in hypertensive patients with AHF.[@B9][@B19] However, these results generally come from observational studies, and evidence-based therapy in AHF is lacking.[@B4][@B20] Indeed, although previous pilot trials, mostly from case reports or case series,[@B14][@B21] have suggested intravenous urapidil as a potential therapeutic option in patients with hypertension and AHF, randomized controlled trials are limited. In this study, we performed a multicenter randomized controlled trial to evaluate the efficacy of intravenous urapidil, compared with the clinically accepted vasodilator nitroglycerin, in older patients with hypertension and AHF. The results of our study, for the first time, to the best of our knowledge, indicated that intravenous urapidil may benefit old hypertensive patients that suffer from AHF by offering more remarkable blood pressure lowering and cardiac protective functions. Our results provided further evidence for the administration of urapidil in patients with hypertension and AHF.

Urapidil is proven to exert its antihypertensive action via both peripheral alpha-adrenergic receptor and central HTR1A antagonizing effects, which make it more effective for the regulation of afterload of the heart.[@B15] Furthermore, early observational studies with animals[@B22] and humans[@B23][@B24] indicated that urapidil could benefit cardiac output. However, the effects of urapidil on cardiac function have rarely been examined in randomized controlled trials. Our results indicated that, although both intravenous urapidil and nitroglycerin were effective in lowering blood pressure in older patients with hypertension and AHF, after 7 days of treatment those in the urapidil group achieved better-preserved cardiac systolic function. The mechanisms underlying the cardioprotective effects of urapidil in these patients, in our opinion, may not be fully explained by its beneficial effect on blood pressure. Indeed, a previous study of patients with coronary heart disease after coronary stenting showed that long-term urapidil may improve LVEF at midterm after coronary revascularization.[@B25] Some recent studies suggested that urapidil treatment may improve myocardial function by increasing coronary flow and myocardial perfusion, thereby optimizing energy metabolism of the myocardium.[@B26]

Although our study was not designed to evaluate the role of urapidil in AHF patients with preserved LVEF, our post-hoc analysis in patients with HFpEF indicated that urapidil may have an immediate inhibitory effect on serum NT-proBNP within 7 days of treatment. Previous studies have indicated that serum NT-proBNP is of significant prognostic value in patients with HFpEF[@B27] and that a rise in NT-proBNP is associated with an increase in risk of adverse cardiovascular outcome (a fall was associated with a decrease in risk).[@B28] From this perspective, the present pilot study suggests that urapidil may be beneficial for AHF patients with HFpEF. It has to be mentioned that our study was not designed with adequate power to evaluate the potential benefits of urapidil in patients with HFpEF, and obviously, further studies are warranted.

An important issue concerning the use of current vasodilators is that they are often poorly tolerated by many AHF patients, due to headache, tachycardia, and flushing.[@B12][@B13] An important finding of the present study was that our older patients with AHF and hypertension were able to tolerate urapidil better than nitroglycerin, being less troubled by headache and tachycardia. Moreover, biochemical indices reflecting hepatic and renal function were not significantly changed after urapidil administration, which further confirmed its safety. Although the efficacy of urapidil failed to confer benefits in terms of improved rates of rehospitalization or mortality at the one-month follow-up, our study was not designed to evaluate these endpoints, and further studies with adequate statistical power are needed.

In conclusion, our study indicates that, for older adults with hypertension and AHF, intravenous administration of urapidil is associated with better control of blood pressure and preserved cardiac function, with fewer adverse side effects, compared to intravenous nitroglycerin. Further studies are warranted to evaluate whether treatment with urapidil in these patients is associated with improved clinical outcomes.
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Baseline Characteristics of the Inlcuded Patients with HFpEF in Both the Groups

###### Supplementary Table 2

Effects of Urapidil on Serum NT-proBNP and LVEF in Patients with HFpEF

![Effects of intravenous urapidil and nitroglycerin on SBP (A), DBP (B), and heart rate (HR) (C) within 7 days after start of treatment for older patients with hypertension and AHF. ^\*^*p*\<0.05 between the treatment groups at the indicated time point. SBP, systolic blood pressure; DBP, diastolic blood pressure; AHF, acute heart failure.](ymj-58-105-g001){#F1}

![Effects of intravenous urapidil and nitroglycerin on serum NT-proBNP (A), LVEF (B), and LVEDV (C) within 7 days after start of treatment for older patients with hypertension and AHF. ^\*^*p*\<0.05 between the treatment groups at the indicated timepoint. LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; NT-proBNP, N-terminal B type natriuretic peptide.](ymj-58-105-g002){#F2}

###### Baseline Characteristics of the Hypertensive Patients in the Nitrlycerin and Urapidil Groups^\*^

![](ymj-58-105-i001)

  Index                                Nitroglycerin   Urapidil    *p* value
  ------------------------------------ --------------- ----------- -----------
  Patients (n)                         91              89          0.456
  Male (n, %)                          54 (59.3)       51 (57.3)   0.423
  Age (yr)                             76.9±11.3       77.5±5.3    0.701
  Duration of hypertension (yr)        23.1±3.2        24.0±1.9    0.321
  HGB (g/L)                            107.0±4.2       106.7±4.6   0.341
  eGFR (mL/min)                        45.2.0±4.8      44.0±4.1    0.319
  HFrEF (n, %)                         57 (62.6)       53 (59.6)   0.142
  HFpEF (n, %)                         34 (37.4)       36 (40.4)   0.421
  LVEF (%)                             36.2±4.2        37.1±4.2    0.243
  NYHA classification (n, %)                                       
   Class II                            39 (42.8)       39 (43.8)   0.654
   Class III                           42 (46.2)       41 (46.1)   0.754
   Class IV                            10 (11.0)       9 (10.1)    0.565
  Comorbidities (n, %)                                             
   CHD                                 27 (29.7)       26 (29.2)   0.867
   DM                                  47 (51.6)       43 (48.3)   0.646
   AF                                  25 (27.5)       26 (29.2)   0.567
  Number of antihypertensives (n, %)                               
   1                                   35 (38.5)       34 (38.2)   0.657
   2                                   45 (49.4)       43 (48.3)   0.765
   3                                   11 (12.1)       12 (13.5)   0.567
  Concurrent CV medications (n, %)                                 
   CCBs                                40 (44.0)       38 (42.7)   0.347
   ACEIs/ARBs                          47 (51.6)       49 (55.1)   0.245
   β-blockers                          38 (41.8)       36 (40.4)   0.364
   Diuretics                           59 (64.8)       57 (64.0)   0.432
   Digoxin                             25 (27.5)       24 (27.0)   0.381

HGB, hemoglobin; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, the New York Heart Association; CHD, coronary heart disease; DM, diabetes; AF, atrial fibrillation; CV, cardiovascular; CCBs, calcium-channel blockers; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

^\*^Reported as mean±standard deviation, unless indicated otherwise.

###### Effects of Urapidil on Serum Biochemical Indices: Comparison with Nitroglycerin^\*^

![](ymj-58-105-i002)

  Index                            Urapidil    Nitroglycerin                                      
  -------------------------------- ----------- --------------- ---------- ----------- ----------- -----------
  ALT, IU/L                        38.1±2.7    35.1±2.7        32.4±4.4   39.2±2.2    37.3±3.2    34.1±3.5
  AST, IU/L                        39.2±1.7    35.7±3.6        33.6±4.7   40.1±3.5    37.5±3.7    35.5±4.7
  Creatinine, µmol/L               126.4±4.7   109.2±2.7       99.3±7.8   125.7±4.7   112.2±5.4   105.5±3.5
  Fasting plasma glucose, mmol/L   7.4±4.7     6.7±2.2         6.3±1.4    7.5±1.4     7.0±1.2     6.3±1.5
  Triglycerides, mmol/L            1.8±1.3     1.6±0.5         1.4±0.5    1.8±0.4     1.6±0.5     1.4±0.2

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^\*^Reported as mean±standard deviation.

###### Adverse Events within the Treatment Period and Clinical Outcomes during 1 Month Follow-Up: Comparison between the Urapidil and Nitroglycerin (Control) Groups

![](ymj-58-105-i003)

  Index                Urapidil   Nitroglycerin   *p* value
  -------------------- ---------- --------------- -----------
  Subjects, n          89         91              0.456
  Adverse events                                  
   Headache            0          7               0.025^\*^
   Flushing            0          3               0.252
   Tachycardia         0          10              0.004^\*^
   Hypotension         1          3               0.628
  Clinical outcomes                               
   Rehospitalization   33         39              0.523
   Death               0          3               0.252

^\*^Significant difference at the level of *p*\<0.05.
